|
Meanwhile, Pfizer is asking advisers to European Union medical regulators to reconsider their recommendation in April not to approve the drug. The advisers said Xeljanz didn't control progression of the immune disorder enough to outweigh serious side effects seen in some patients. Those include blood and other cancers, perforated intestines, tuberculosis and other infections, decreased infection-fighting cells, headaches and diarrhea. Nearly 24 million people worldwide suffer from rheumatoid arthritis, a painful, often disabling immune disorder. Many aren't satisfied with current treatments.
[Associated
Press;
Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.